Experience with low-dose methotrexate: Toxicity, tolerability and effect on conventional patterns of drug therapy for inflammatory arthritis

1995 ◽  
Vol 14 (5) ◽  
pp. 544-550 ◽  
Author(s):  
M. Nisar ◽  
L. Carlisle ◽  
R. Amos
2019 ◽  
Vol 191 (15) ◽  
pp. E423-E423 ◽  
Author(s):  
Kevin Pivovarov ◽  
Jonathan S. Zipursky

2019 ◽  
Vol 4 (4) ◽  

Methotrexate toxicity has been widely shown to cause myelosuppression but the literature demonstrating low doses of the drug causing the same issue is much scarcer. Our patient presented with severe pancytopenia which began to improve with treatment but she ultimately succumbed to a superimposed pneumonia.


2014 ◽  
Vol 13 (11) ◽  
pp. 1109-1113 ◽  
Author(s):  
Shaye Kivity ◽  
Yaron Zafrir ◽  
Ronen Loebstein ◽  
Rachel Pauzner ◽  
Meir Mouallem ◽  
...  

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Miguel A. Jara-Palacios ◽  
William Chun ◽  
Nomi L. Traub

Abstract Background Low dose methotrexate toxicity rarely occurs, but may present with severe complications, such as pancytopenia, hepatotoxicity, mucositis, and pneumonitis. Known risk factors for methotrexate toxicity include dosing errors, metabolic syndrome, hypoalbuminemia, renal dysfunction, lack of folate supplementation, and the concomitant use of drugs that interfere with methotrexate metabolism. Vitamin B12 deficiency leads to megaloblastic anemia and may cause pancytopenia, but its role in methotrexate toxicity has not been described. Case presentation We present a case of a patient with rheumatoid arthritis who was admitted with febrile neutropenia, pancytopenia, and severe mucositis, likely secondary to low dose methotrexate toxicity. She had multiple factors that potentially contributed to the development of toxicity, including concurrent sulfasalazine use for rheumatoid arthritis. An evaluation of the patient’s macrocytic anemia revealed pernicious anemia. The patient’s illness resolved with cessation of methotrexate and sulfasalazine, leucovorin treatment and vitamin B12 repletion. Conclusions This case illustrates the multiple factors that may potentially contribute to low dose methotrexate toxicity and highlights the importance of testing for vitamin B12 deficiency in rheumatoid arthritis patients with macrocytic anemia. Addressing all the modifiable factors that potentially contribute to low dose methotrexate toxicity may improve outcomes.


CHEST Journal ◽  
2019 ◽  
Vol 155 (4) ◽  
pp. 100A ◽  
Author(s):  
W. Grist ◽  
Y. Elamir

2020 ◽  
Vol 8 (7) ◽  
pp. 206-209
Author(s):  
Lubaina Haider ◽  
Sara Sharif ◽  
Abida Hasan ◽  
Isabel M. McFarlane

Sign in / Sign up

Export Citation Format

Share Document